| CSPC Pharmaceutical Group Limited24 programs in shared conditions | 10 · 2 with both in phase 3Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms +7 | Docetaxel, anbenitamab, anbenitamab repodatecan +5 | - CSPC Pharmaceutical Group Limited’s anbenitamab repodatecan vs pertuzumab (US rights: Hoffmann-La Roche) (Breast Neoplasms, NCT07545044)
- CSPC Pharmaceutical Group Limited’s anbenitamab repodatecan vs Ado-Trastuzumab Emtansine (US & EU rights: Hoffmann-La Roche) (Breast Neoplasms, NCT06846437)
- CSPC Pharmaceutical Group Limited’s anbenitamab in a combination vs pertuzumab (US rights: Hoffmann-La Roche) (Breast Neoplasms, NCT06747338)
- and 6 more
|
| Bristol-Myers Squibb26 programs in shared conditions | 10 · 3 with both in phase 3Alzheimer Disease, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma +7 | xanomeline, trospium, trospium chloride +7 | - Hoffmann-La Roche’s divarasib vs Nivolumab (US & EU rights: Bristol-Myers Squibb) (Carcinoma, Non-Small-Cell Lung, NCT07541170)
- Hoffmann-La Roche’s divarasib vs adagrasib (US & EU rights: Bristol-Myers Squibb) (Carcinoma, Non-Small-Cell Lung, NCT06497556)
- Hoffmann-La Roche’s cevostamab in a combination vs elotuzumab (US & EU rights: Bristol-Myers Squibb) (Multiple Myeloma, NCT07555938)
- and 1 more
|
| Pfizer30 programs in shared conditions | 16 · 7 with both in phase 3Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colitis, Ulcerative +13 | atirmociclib, prifetrastat, sigvotatug vedotin +8 | - Pfizer’s tucatinib added to pertuzumab (US rights: Hoffmann-La Roche) (Breast Neoplasms, NCT05132582)
- Hoffmann-La Roche’s giredestrant added to palbociclib (US rights: Pfizer) (Breast Neoplasms, NCT04546009)
- Hoffmann-La Roche’s inavolisib in a combination vs palbociclib (US rights: Pfizer) (Breast Neoplasms, NCT03424005)
- and 6 more
|
| Novartis40 programs in shared conditions | 15 · 3 with both in phase 3Breast Neoplasms, Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive +12 | inclisiran, pelacarsen, Alpelisib +4 | - Novartis’s remibrutinib vs ocrelizumab (US & EU rights: Hoffmann-La Roche) (Multiple Sclerosis, NCT06846281)
- Novartis’s Alpelisib added to pertuzumab (US rights: Hoffmann-La Roche) (Breast Neoplasms, NCT04208178)
- Hoffmann-La Roche’s giredestrant added to Everolimus (EU rights: Novartis) (Breast Neoplasms, NCT05306340)
- and 5 more
|
| Merck & Co., Inc24 programs in shared conditions | 17 · 5 with both in phase 3Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colitis, Ulcerative +14 | patritumab deruxtecan, sacituzumab tirumotecan, intismeran autogene +9 | - Hoffmann-La Roche’s divarasib vs pembrolizumab (US & EU rights: Merck & Co., Inc) (Carcinoma, Non-Small-Cell Lung, NCT07541170)
- Hoffmann-La Roche’s divarasib added to pembrolizumab (US & EU rights: Merck & Co., Inc) (Carcinoma, Non-Small-Cell Lung, NCT06793215)
- Merck & Co., Inc’s zilovertamab vedotin in a combination vs polatuzumab vedotin (US & EU rights: Hoffmann-La Roche) (Lymphoma, Large B-Cell, Diffuse, NCT06890884)
- and 3 more
|